These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 24485876)
41. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Shum T; Kruse RL; Rooney CM Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246 [TBL] [Abstract][Full Text] [Related]
42. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? Madden DL Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148 [TBL] [Abstract][Full Text] [Related]
43. Personalized Immuno-Oncology. Jain KK Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942 [TBL] [Abstract][Full Text] [Related]
44. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Shi T; Song X; Wang Y; Liu F; Wei J Front Immunol; 2020; 11():683. PubMed ID: 32411132 [TBL] [Abstract][Full Text] [Related]
45. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects. Guo H; Qian X Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487 [TBL] [Abstract][Full Text] [Related]
47. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J Front Immunol; 2018; 9():947. PubMed ID: 29770138 [TBL] [Abstract][Full Text] [Related]
48. The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors. Zander R; Cui W Hum Vaccin Immunother; 2017 Oct; 13(10):2269-2271. PubMed ID: 28708956 [TBL] [Abstract][Full Text] [Related]
50. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors]. Catros V Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109 [TBL] [Abstract][Full Text] [Related]
51. Natural killer cells: from bench to cancer therapy. Boyiadzis M; Foon KA Expert Opin Biol Ther; 2006 Oct; 6(10):967-70. PubMed ID: 16989578 [TBL] [Abstract][Full Text] [Related]
52. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789 [TBL] [Abstract][Full Text] [Related]
53. Applications of gene transfer to cellular immunotherapy. Terando A; Chang AE Surg Oncol Clin N Am; 2002 Jul; 11(3):621-43. PubMed ID: 12487059 [TBL] [Abstract][Full Text] [Related]
54. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Jäkel CE; Schmidt-Wolf IG Expert Opin Biol Ther; 2014 Jul; 14(7):905-16. PubMed ID: 24673175 [TBL] [Abstract][Full Text] [Related]
55. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. Kim SJ; Ha GH; Kim SH; Kang CD Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450 [TBL] [Abstract][Full Text] [Related]
56. Adoptive T-Cell Therapy for Solid Malignancies. Jafferji MS; Yang JC Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800 [TBL] [Abstract][Full Text] [Related]
57. Adoptive Cell Therapy in Treating Pediatric Solid Tumors. Tesfaye M; Savoldo B Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644 [TBL] [Abstract][Full Text] [Related]